Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AV-1 in Healthy Adults
NCT04273217Phase 1Completed
- Sponsor
- AbViro LLC
- Start
- Feb 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AV-1 in dengue fever (6 arms), sponsored by AbViro LLC. Primary endpoints: Number of Participants With Clinical Laboratory, Physical Examination, Vital Sign, and ECG Abnormalities Reported as TEAEs at Day 120, Number of Participants With Serious Adverse Events (SAEs) at Day 120 and 1 more. Started Feb 2020; status: completed.
02
Drugs
AV-1
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT04273217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273217.